Novartis Signs Worldwide License Agreement with Forendo Pharma to Discover Therapies Targeting Chronic Liver Diseases
Shots:
- Forendo to receive up front- equity investment- development- regulatory and commercial milestones with royalties on sales. Novartis to fund the research activities and will be responsible for development- manufacturing & commercialization of novel therapies
- Forendo has its expertise in an enzyme family called HSD17B (17-beta-hydroxysteroid dehydrogenase) responsible for regulating hormone action with its lead candidate- FOR-6219 currently being evaluated in P-I clinical study for endometriosis
- With the collaboration- Novartis acknowledges Forendo's core capabilities and the scope of its enzyme family in other therapeutic areas in addition to women's health
Source 1- Source 2 to read full press release/ article | Ref: GlobeNewswire- PRNewswire | Image: Forendo Pharma
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com